- Home
- FGEN vs RDI Comparison
FGEN vs RDI Comparison
Compare FGEN & RDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGEN
- RDI
- Stock Information
- Founded
- FGEN 1993
- RDI 1937
- Country
- FGEN United States
- RDI United States
- Employees
- FGEN N/A
- RDI N/A
- Industry
- FGEN Biotechnology: Pharmaceutical Preparations
- RDI Movies/Entertainment
- Sector
- FGEN Health Care
- RDI Consumer Discretionary
- Exchange
- FGEN Nasdaq
- RDI Nasdaq
- Market Cap
- FGEN 33.5M
- RDI 30.1M
- IPO Year
- FGEN 2014
- RDI N/A
- Fundamental
- Price
- FGEN $0.31
- RDI $1.33
- Analyst Decision
- FGEN Strong Buy
- RDI Hold
- Analyst Count
- FGEN 1
- RDI 1
- Target Price
- FGEN $10.00
- RDI $2.40
- AVG Volume (30 Days)
- FGEN 514.9K
- RDI 33.3K
- Earning Date
- FGEN 05-12-2025
- RDI 05-19-2025
- Dividend Yield
- FGEN N/A
- RDI N/A
- EPS Growth
- FGEN N/A
- RDI N/A
- EPS
- FGEN N/A
- RDI N/A
- Revenue
- FGEN $29,621,000.00
- RDI $210,527,000.00
- Revenue This Year
- FGEN $232.81
- RDI $9.74
- Revenue Next Year
- FGEN $9.16
- RDI $6.39
- P/E Ratio
- FGEN N/A
- RDI N/A
- Revenue Growth
- FGEN N/A
- RDI N/A
- 52 Week Low
- FGEN $0.18
- RDI $1.17
- 52 Week High
- FGEN $1.74
- RDI $1.89
- Technical
- Relative Strength Index (RSI)
- FGEN 46.75
- RDI 52.82
- Support Level
- FGEN $0.28
- RDI $1.23
- Resistance Level
- FGEN $0.34
- RDI $1.30
- Average True Range (ATR)
- FGEN 0.02
- RDI 0.07
- MACD
- FGEN 0.00
- RDI 0.01
- Stochastic Oscillator
- FGEN 37.50
- RDI 50.00
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.
About RDI Reading International Inc
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial, and live theater assets.